相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines
Youfeng Yang et al.
GENES CHROMOSOMES & CANCER (2021)
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Sumanta K. Pal et al.
LANCET (2021)
Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90
Shuai Zhao et al.
SCIENTIFIC REPORTS (2021)
Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).
Yoshitaka Honma et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma The SAVOIR Phase 3 Randomized Clinical Trial
Toni K. Choueiri et al.
JAMA ONCOLOGY (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study
Zhebin Du et al.
BIOMARKER RESEARCH (2020)
Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma
Rong Deng et al.
MOLECULAR CANCER (2020)
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
Katherine Emilie Rhoades Smith et al.
KIDNEY CANCER (2019)
Targeting loss of the Hippo signaling pathway in NF2-deficient papillary kidney cancers
Carole Sourbier et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Regulation of the master regulator FOXM1 in cancer
Guo-Bin Liao et al.
CELL COMMUNICATION AND SIGNALING (2018)
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Current Treatment Landscape of Advanced Papillary Renal Cancer
Brian Shuch et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The HSP90 chaperone machinery
Florian H. Schopf et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2017)
A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage
Mariana F. Gayyed et al.
TUMOR BIOLOGY (2016)
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
Nizar M. Tannir et al.
EUROPEAN UROLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Long noncoding RNA AK126698 inhibits proliferation and migration of non-small cell lung cancer cells by targeting Frizzled-8 and suppressing Wnt/beta-catenin signaling pathway
Xiao Fu et al.
ONCOTARGETS AND THERAPY (2016)
Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
Yongpeng Xie et al.
SCIENTIFIC REPORTS (2016)
Implications of Genetic and Epigenetic Alterations of CDKN2A (p16INK4a) in Cancer
Ran Zhao et al.
EBIOMEDICINE (2016)
Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?
Yao Wang et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Spectrum of diverse genomic alterations define non-clear cell renal carcinoma
Steffen Durinck et al.
NATURE GENETICS (2015)
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
Jeffrey R. Infante et al.
EUROPEAN JOURNAL OF CANCER (2014)
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
Lesley A. Mathews Griner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
Naoto Miyajima et al.
CANCER RESEARCH (2013)
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Trial of the HSP90 Inhibitor PF-04929113 (SNX5422) in Adult Patients With Recurrent, Refractory Hematologic Malignancies
Nishitha Reddy et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers et al.
CLINICAL CANCER RESEARCH (2012)
Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Thomas Bachleitner-Hofmann et al.
CLINICAL CANCER RESEARCH (2011)
An overview of the c-MET signaling pathway
Shawna Leslie Organ et al.
Therapeutic Advances in Medical Oncology (2011)
The genetic basis of kidney cancer: a metabolic disease
W. Marston Linehan et al.
NATURE REVIEWS UROLOGY (2010)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa et al.
BLOOD (2009)
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2008)
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
J. A. McCubrey et al.
LEUKEMIA (2008)
Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer
Yoshiaki Yamamoto et al.
CANCER GENETICS AND CYTOGENETICS (2007)
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
Ellen A. Ronnen et al.
INVESTIGATIONAL NEW DRUGS (2006)
Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2Rγnull mice engrafted with mobilized human hemopoietic stem cells
LD Shultz et al.
JOURNAL OF IMMUNOLOGY (2005)
Modulation of Akt kinase activity by binding to Hsp90
S Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
